Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer

Prior treatment

• Current or previous active malignancy other than rectal cancer；
• Patients underwent major surgery within 4 weeks prior to neoadjuvant therapy；
• Patients have severe uncontrolled recurrent infections, or other severe uncontrolled concomitant diseases;
• Patients with severe concomitant diseases with estimated survival≤5 years；
• Patients with present or previous moderate or severe liver and kidney damage；
• Patients preparing for or previously received organ or bone marrow transplant；
• Patients who have received immunosuppressive or systemic hormone therapy within 1 month prior to the start of neoadjuvant therapy；

Other illness

• Patients have any condition affects the absorption of capecitabine through gastrointestinal tract；
• Patients with congenital or acquired immune deficiency (such as HIV infection)；

Other

• Pregnant or lactating women.

• Patients with rectal adenocarcinoma must satisfied all the following conditions:
  • Stage II/III LARC (cT1-4aN0-2M0);
  • Tumor distal location≤10 cm from anal verge (MRI diagnosed);
• Patients regardless of gender with aged≥18 years
• ECOG score of 0 or 1
• Physical and viscera function of patients can withstand major abdominal surgery